Introduction {#sec1}
============

Glycosidases play a key role in intestinal digestion, post-translational processing of glycoproteins, endoplasmic reticulum-associated degradation mechanisms, and the lysosomal catabolism of glycoconjugates.^[@ref1]^ Any malfunction in this process leads to discomforts in the body, and in case of long-run processes, one suffers from disease.^[@ref2]^ For example, disorders in functioning of amylase and/or α-glucosidase enzymes results in alteration in the blood glucose level, a condition noted as diabetes mellitus type-II (DM-II).^[@ref3]^ Patients suffering from long-term DM-II develop low immunity^[@ref4]^ and fall as a prey to a variety of comorbidities, such as retinopathy,^[@ref5]^ nephropathy,^[@ref6]^ neuropathy,^[@ref7]^ infections,^[@ref8]^ and many more.^[@ref9]^ In particular, sugar damp in diabetes nurtures the infections of *Candida albicans* yeast in mouth, skin, nails, and surroundings of urethral openings.^[@ref10]^ In such cases of comorbidity discomforts, an effective treatment is a challenge and prescription of two separate drugs is a common medicinal practice. Among a variety of antidiabetic drugs, an iminosugar (cyclic sugars with the nitrogen atom in place of the ring oxygen atom) class of compound, namely, glycet/miglitol **I** ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) is consumed for the treatment of DM-II,^[@ref11]^ whereas, for the treatment of fungal infection, 1,2,4-triazole-containing drug fluconazole^[@ref12]^ is practiced. Alternatively, hybrid/chimeric drugs, in which two pharmacophores are present in one molecule and thus showing dual therapeutic mechanism, would have been the most appropriate choice.^[@ref13],[@ref14]^ In this direction, a number of hybrid drugs were synthesized and evaluated for biological activities.^[@ref14]^ Among these, iminosugars attached with other pharmacophores have attracted a great deal of interest.^[@ref1],[@ref15]^ For example, iminosugar fused with tetrazole **II** ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) showed antitubercular as well as α-rhamnosidase inhibitory activity.^[@ref16]^ Iminosugar fused with imidazole ring, namely, nagstatin (**III**) is an *N*-acetyl-β-glucosaminidase inhibitor and acts as an anticancer agent,^[@ref1],[@ref17]^ whereas iminosugar fused with 1,2,4-triazole **IV** shows inhibition toward α-mannosidase along with anticancer activity.^[@ref1]^ A few examples of the iminosugars spiro-linked with other pharmacophores are also known.[a](#fna){ref-type="fn"}^,[@ref18]^ Laroche et al. reported a titanium-mediated aminocyclopropanation of nitriles to give pyrrolidine iminosugar spiro-linked with cyclopropane **V**.^[@ref19]^ Vankar and co-workers utilized the RCM strategy in the synthesis of iminosugar spiro-linked with the sugar pyranose **VI**.^[@ref20]^ Compain and co-workers used C--H amination and RCM methodology to build 5-azaspiro\[3,4\]octane **VII** skeleton.^[@ref21]^

![Known iminosugars and target molecules.](ao-2017-01299m_0004){#fig1}

Our group has exploited Corey-link approach with 3-oxo-1,2;5,6-diisopropylidene-[d]{.smallcaps}-gluco-furanose to give C~3~-azido-3-formyl-substituted [d]{.smallcaps}-gluco-furanose that was elaborated toward the synthesis of spiro-iminosugars **VIIIa**/**VIIIb**, which showed a promising α-glucosidase inhibitory activity.^[@ref22]^ In the continuation of our work, we now report the synthesis of tricyclic azepine **1**, piperidine iminosugars **2**, **3a**--**g**, and iminosugars **4a**--**g** spiro-linked with the morpholine-fused 1,2,3-triazol. The conformations ^1^*C*~4~/^4^*C*~1~ were obtained on the basis of the ^1^H NMR study and substantiated by density functional theory (DFT) studies. The glycosidase inhibitory and antifungal (on *Candida albicans* yeast cells) activities were evaluated. Among the 16 targeted molecules, iminosugar **3a** (IC~50~ = 0.075 μM) and iminosugar **4a** (IC~50~ = 0.036 μM) were found to be highly potent α-glucosidase inhibitors compared to miglitol **I** (IC~50~ = 0.100 μM). In addition, **3a** (minimum inhibition concentration (MIC) = 0.85 μM) and **4a** (MIC = 0.025 μM) were noticed to be highly potent antifungal agents compared to marketed drug amphotericin b (MIC = 1.25 μM). As the hybrid drugs are known to increase cellular uptake that augment the specific pharmacological activity,[b](#fnb){ref-type="fn"}^,[@ref23]^ an analogous trend was noticed with the spiro-iminosugars **1**, **2**, **3a**--**g**, and **4a**--**g** in the augmentation of the glycosidase inhibitory as well as antifungal activity due to the presence of iminosugar and triazole pharmacophores in the same molecule. Our results toward the synthesis, conformations, glycosidase, and antifungal activity as well as molecular docking studies of spiro-iminosugars are described herein.

Results and Discussion {#sec2}
======================

Synthesis of Spiro-Iminosugars (**1**, **2**, **3a--g**, and **4a--g**) {#sec2.1}
-----------------------------------------------------------------------

Recently, we have studied the role of *gem*-disubstituent effect in intramolecular alkyne-azide 1,3-dipolar cycloaddition (AAC) reaction with O-propargylated azido compounds **IXa**--**d** by experimental kinetic data and thermodynamic parameters obtained from computational studies ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}).^[@ref24]^ During this study, we noticed that the AAC reaction of 1,2;5,6-di-*O*-isopropylidene-3-*O*-propargyl-3-azido-[d]{.smallcaps}-glucofuranose **IXd** in the presence or absence of solvent occurred spontaneously at ambient temperature to afford morpholine-fused 1,2,3,-triazole moiety spirocyclic with [d]{.smallcaps}-gluco-furanose **5** in 89% yield. We thought of exploiting the same intermediate **5**, by suitable manipulation of 5,6- and 1,2-*O*-isopropylidene groups of [d]{.smallcaps}-gluco-furanose, for the synthesis of targeted spiro-iminosugars.

![Catalyst-free AAC reaction in **IXa--d**.](ao-2017-01299m_0010){#fig2}

As shown in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, selective deprotection of 5,6-*O*-isopropylidene group in **5** with AcOH/H~2~O (3:2) at 60 °C afforded diol **6**. The primary hydroxyl group in **6** was protected as −*O*Ts group using Bu~2~SnO and TsCl in triethylamine to get **7**, which on nucleophilic displacement of C6--*O*Ts group with NaN~3~ in dimethylformamide (DMF) afforded C6-- azido compound **8** in 89% yield. In the next step, hydrolysis of 1,2-*O*-isopropylidene group in **8** with TFA/H~2~O (3:1) at 0 °C gave an anomeric mixture of hemiacetal (as evident from the ^1^H NMR of crude product), which on intramolecular reductive aminocyclization under hydrogenation condition, using 10% Pd/C in methanol at 80 psi pressure, gave azepine iminosugar spiro-linked with the morpholine-fused 1,2,3-triazole **1** in 71% yield.

![Synthesis of Spiro-Iminosugars **1** and **2**\
Reagents and conditions: (i) 60% aq AcOH, 60 °C, 3 h, 92%; (ii) Bu~2~SnO, TsCI, tetraethylammonium (TEA), room temperature (RT), 1 h, 97%; (iii) NaN~3~, tetrabutylammonium iodide (TBAI), DMF, 95 °C, 3 h, 89%; (iv) (a) TFA/H~2~O (3:1), 0 °C, 3 h, (b) 10% Pd/C, H~2~, 80 psi, 24 h, RT, 71%; (v) BnBr, NaH, THF, 0 °C to RT, 3 h, 75%; (vi) (a) TFA/H~2~O (3:1), RT, 3 h, (b) NalO~4~, acetone/water (8:2), 3 h, (c) 10% Pd/C, H~2~, 120 psi, 30 h, 68%.](ao-2017-01299m_0008){#sch1}

For the synthesis of spiro-iminosugar **2**, it is necessary to remove anomeric C1 carbon atom in compound **8**, for which it is necessary to protect C5--*O*H group with benzyl derivative. Thus, **8** was reacted with NaH and benzyl bromide in THF to get 6-azido 5-benzyloxy derivative **9** ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). Hydrolysis of 1,2-acetonide in **9** with TFA/H~2~O (3:1) followed by treatment with NaIO~4~ in acetone/H~2~O (8:2) and intramolecular reductive aminocyclization of C6-- azido group with C2-- formyl group using H~2~ in 10% Pd/C at 120 psi afforded piperidine iminosugar spiro-linked with morpholine-fused 1,2,3-triazole **2** in 68% yield.

The synthesis of iminosugar **3a** started from the diol **6**. Thus, reaction of **6** with NaIO~4~ in acetone/H~2~O (8:2) at 0 °C to RT followed by treatment with NaBH~4~ in MeOH at 0 °C afforded [d]{.smallcaps}-xylofuranose derivative **10** ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). Compound **10** was treated with TsCl in pyridine to give −*O*Ts derivative **11**, which on nucleophilic displacement using NaN~3~ in DMF afforded C5-- azido compound **12**. Finally, hydrolysis of 1,2-acetonide group in **12** with TFA/H~2~O (3:1) followed by intramolecular aminocyclization using H~2~ in 10% Pd/C at 100 psi afforded **3a** in 86% yield. In general, the N-alkylated derivatives of iminosugars showed enhanced glycosidase inhibitory activity compared to their parent iminosugars.^[@ref25]^ Thus, reaction of **3a** with different alkyl bromides (alkyl = ethyl, butyl, hexyl, octyl, decyl, and dodecyl) in the presence of K~2~CO~3~ in DMF at 80 °C afforded corresponding N-alkyl derivatives **3b**--**g** in good yield ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}).

![Synthesis of Spiro-Iminosugars **3a**--**g** and **4a**--**g**\
Reagents and conditions: (i) (a) NalO~4~, acetone/water (4:1), 0 °C to RT 2 h, (b) NaBH~4~, MeOH, 0 °C, 1 h, 88% two steps; (ii) TsCI, pyridine, DCM, 0 °C to RT, 4 h, 95%; (iii) NaN~3~, TBAI, DMF, 95 °C, 6 h 86%; (iv) 10% Pd/C, H~2~, 100 psi, 30 h, RT, 86%; (v) for **b** ethylbromide, for **c** butylbromide, for **d** hexylbromide, for **e** octylbromide, for **f** decylbromide, for **g** dodecylbromide, K~2~CO~3~, DMF, 80 °C, 1 h, and for 3**b**--**g**, 60 °C, 2 h for 4**b**--**g**; (vi) TBDMSCI, imidazole, DCM, 2 h, RT, 95%; (vii) (a) OTf~2~, pyridine, DMAP, DCM, 0 °C, 30 min, (b) NaN~3~, DMF, 65 °C, 1 h, 92% two steps; (viii) (a) TFA/H~2~O (3:1), 3 h, 0 °C, (b) 10% Pd/C, H~2~, 120 psi, 24 h, RT, 78%.](ao-2017-01299m_0003){#sch2}

Iminosugar **4a** was prepared from compound **6** ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). Thus, selective protection of C6-- primary hydroxy functionality in **6** with TBDMSCl in the presence of imidazole in dry dichloromethane afforded C6--OTBDMS compound **13**. Reaction of **13** with triflic anhydride in Et~3~N in dry dichloromethane afforded C5--*O*Tf derivative, which was directly treated with NaN~3~ in DMF to get C5-- azido derivative **14** with inversion of configuration at C5, as evident from the ^1^H NMR spectrum (*J*~4,5~ = 1.5 Hz in [l]{.smallcaps}-ido derivative against *J*~4,5~ = 6.0 Hz in [d]{.smallcaps}-gluco derivative in **13**). Finally, cleavage of 1,2-acetonide group in **14** with TFA/H~2~O (3:1) and intramolecular reductive aminocyclization with H~2~ in 10% Pd/C in MeOH at 120 psi and room temperature afforded **4a** in 78% yield. N-Alkylations of **4a** with alkyl bromides (alkyl = ethyl, butyl, hexyl, octyl, decyl, and dodecyl) using K~2~CO~3~ in DMF at 60 °C afforded N-alkyl iminosugars **4b**--**g**, respectively ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}).

Conformational Analysis for **2**, **3a**--**g**, and **4a**--**g** {#sec2.2}
-------------------------------------------------------------------

It is known that six-membered piperidine iminosugars exist in ^4^*C*~1~ or ^1^*C*~4~ conformations, depending on the substituents present on the ring.^[@ref26]^ These conformations play a key role in deciding the binding property of iminosugars with enzymes rendering the glycosidase inhibition activity.^[@ref27]^ In view of this fact, conformational aspects of newly synthesized spiro-linked iminosugars **2**, **3a**--**g**, and **4a**--**g** were studied using ^1^H NMR spectroscopy at neutral pH. In case of iminosugar **2**, the assignment of H3 and H4 proton signals was difficult as these protons were obscured in the deuterated water (HOD). To resolve the spectra, we studied the temperature-dependent ^1^H NMR spectrum of **2** in D~2~O as the HOD signal at δ 4.85 and 22 °C is known to shift upfield with increasing the temperature, and at 72 °C, it appears at δ 4.30.^[@ref28]^ Therefore, the ^1^H NMR spectrum of **2** in D~2~O was recorded at different temperatures of 22, 32, 52, and 72 °C ([Figure S13](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01299/suppl_file/ao7b01299_si_001.pdf)). At 72 °C, the doublet at δ 4.72 with *J* = 3.2 Hz was assigned to H3 and a narrow multiplate at δ 4.20 was assigned to H4 on the basis of the DEPT-135, ^1^H--^1^H COSY, and ^1^H--^13^C HSQC NMR techniques ([Figures S14--S16](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01299/suppl_file/ao7b01299_si_001.pdf)). The protons appearing at δ 3.10 (dd, *J* = 14.4, 1.5 Hz, 1H) and δ 2.97 (dd, *J* = 14.4, 2.0 Hz, 1H) were assigned to H5e and H5a, respectively. Other signals were unchanged, indicating no change in the conformation of **2** even at high temperature. With these ^1^H NMR data, two conformations ^4^*C*~1~ and ^1^*C*~4~ were considered for compound **2**. The coupling constants between H5a (axial) and H4 and between H4 and H3 are decisive in determining the conformation.

In the ^1^H NMR spectrum of **2**, a small coupling constant value between H5a/H5e and H4 (*J* ≈ 1.7 Hz) indicated the cis-relative stereochemistry with the equatorial orientation of H4 ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). In accordance with this, H3 (axial) appeared as a doublet with a small coupling constant value (*J*~4,5~ = 3.2 Hz), showing cis-relative stereochemistry between H3 and H4. On the basis of these data, the ^1^*C*~4~ conformation was assigned to spiro-iminosugar **2** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). The single crystal for **2** was developed in CHCl~3~/MeOH, and X-ray crystallographic analysis supported the ^1^*C*~4~ conformation ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}).

![Conformations of spiro-iminosugars **2**, **3a**--**g**, and **4a**--**g** and ORTEP diagram of **2** and **3a**.](ao-2017-01299m_0001){#fig3}

The spiro-linked iminosugar **3a** is symmetric. Therefore, H1 and H5 protons (both axial and equatorial) as well as H2 and H4 protons are identical. The equivalent H1a and H5a showed dd at δ 2.84 with *J* = 13.4 and 10.8 Hz. The large coupling constant of 10.8 Hz between H1a and H2 or between H5a and H4 requires axial orientation of both H2 and H4 protons with trans-relative stereochemistry, thus suggesting the ^4^*C*~1~ conformation to **3a** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). The single crystal of **3a** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}) was obtained in CHCl~3~/MeOH, and X-ray crystallographic study supported the ^4^*C*~1~ conformation. The N-alkyl derivatives of **3a**, namely, **3b**--**g** also showed ^4^*C*~1~ conformation analogous to parent compound **3a** on the basis of their nearly identical *J* values ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}).

In case of spiro-linked iminosugar **4a**, the H1a (axial) proton appeared at δ 3.07 as a dd ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}) with *J* = 14.8 and 3.3 Hz and H1e was observed at δ 3.60 as dd with *J* = 14.4 and 3.3 Hz. Accordingly, H2 appeared at as a triplet with *J* = 3.3 Hz. The small coupling constant value between H1a and H2 requires equatorial orientation of H2 (cis-relative stereochemistry), thus accounting for the ^1^*C*~4~ conformation of compound **4a**. This fact is further supported by H4, which appeared as a doublet at δ 4.11 with small *J*~4,5~ = 2.6 Hz, indicating equatorial orientation of H4. We presume that the ^1^*C*~4~ conformation is stabilized due to the equatorial orientation of CH~2~OH as well as intramolecular H-bonding between the C2 and C4--*O*H groups, as shown in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}. In case of N-alkyl derivatives **4b**--**g**, we noticed the change in conformation ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}) as H1a appeared as dd with *J* ≈ 12.9 and ≈ 8.0 Hz. The large coupling constant between H1a and H2 requires relative trans-diaxial orientation suggesting ^4^*C*~1~ conformation.

The conformational preferences were supported by the DFT calculations. Thus, DFT-optimized geometries of conformations ^1^*C*~4~/^4^*C*~1~ for compounds **3a**, **3c**, **4a**, and **4c** were subjected for hydrogen-bonding interaction analysis ([Table S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01299/suppl_file/ao7b01299_si_001.pdf)) and are represented in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}.[c](#fnc){ref-type="fn"}

![Geometrically DFT-optimized conformations of **3a**, **3c**, **4a**, and **4c** and their energies.](ao-2017-01299m_0002){#fig4}

As shown in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}a, the adopted ^4^*C*~1~ conformation of **3a** that is stabilized by intramolecular O6···H--O4, N3···H--O2, and O2···H--C6 hydrogen-bonding interactions was found to be energetically more stable by −5.64 kcal/mol over its ^1^*C*~4~ conformation. In ^4^*C*~1~ conformation, the O6···H--O4 interaction was found to be strong as compared to ^1^*C*~4~ conformation. Further, the weak interactions between N3···H--C2 and N3···H--C4 provided additional stability to ^4^*C*~1~ conformation. Similarly, N-butyl analogue **3c** also adopted the same ^4^*C*~1~ conformation, which is stable by −9.41 kcal/mol as compared to its ^1^*C*~4~ conformation ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}b, [Table S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01299/suppl_file/ao7b01299_si_001.pdf)). This conformation was stabilized by hydrogen-bonding interactions between O6···H--O4, N3···H--O2, and N3···H--C2.

In case of compound **4a**, the DFT-optimized ^1^*C*~4~ conformation, which is stabilized by O7···H--O4, O4···H--O2, O6···H--N1, and N1···H--O2 interactions ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}c), was found to be more stable by −4.39 kcal/mol as compared to the ^4^*C*~1~ conformation. The preference of bulkier C6 hydroxy methylene group toward the equatorial orientation (that avoids 1,3-diaxial steric interactions) might be contributing in stability of ^1^*C*~4~ conformation by lowering its energy. However, the optimized geometry of *N*-butyl derivative **4c** was adopted ^4^*C*~1~ conformation, which is more stable by −6.90 kcal/mol over its ^1^*C*~4~ ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}d). The preference of ^4^*C*~1~ conformation was supported by strong H-bonding between O7···H--O4, O4···H--O6, and N3···H--O2 and by weak N3···H--C2, N3···H--C4, and O2···H--C4 interactions. This leads to axial orientation of hydroxy methylene group, which is stabilized by the O4···H--O6 interaction in **4c**.

Biological Activities {#sec2.3}
---------------------

### Glycosidase Inhibitory Activity {#sec2.3.1}

The newly synthesized spiro-iminosugars (**1**, **2**, **3a**--**g**, and **4a**--**g**) were evaluated for their inhibitory activity against a number of commercially available glycosidases, such as α-glucosidase (rice) \[E.C.3.2.1.20\], β-glucosidase (rice) \[E.C.3.2.1.21\], α-galactosidase (bovine liver) \[E.C.3.2.1.22\], β-galactosidase (bovine liver, cytosolic) \[E.C.3.2.1.23\], and α-mannosidase (Jack beans) \[E.C.3.2.1.24\], with reference to known standards, namely, miglitol (*N*-hydroxyethyl 1-deoxynojirimycin, trade name Glycet) and 1-deoxynojirimycin (DNJ). The corresponding IC~50~ values and inhibition constants (*K*~i~) were determined from Lineweaver--Burk plots ([Figures S55--S59](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01299/suppl_file/ao7b01299_si_001.pdf)), and the results are summarized in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. The six-membered (piperidine) and seven-membered (azepine) iminosugars are known to be α-glucosidase inhibitors among various glycosidases, and the same trend was noticed with **1**, **2**, **3a**--**g**, and **4a**--**g** that showed good to potent inhibition of α-glucosidase. In addition, compounds **1**, **2**, **3a**--**g**, and **4a**--**g** were found to be selective inhibitors of α-glucosidase ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}), wherein the spiro-iminosugar **2** (IC~50~ = 0.159 and *K*~i~ = 0.129 μM) was found to be a weak inhibitor of α-glucosidase, whereas **4a** (IC~50~ = 0.036 and *K*~i~ = 0.033 μM) was found to a better inhibitor of α-glucosidase than miglitol (IC~50~ = 0.1 and *K*~i~ = 0.081 μM). This fact could be attributed to the synergetic effect of two pharmacophores, namely, iminosugar and 1,2,3-triazole (known to be α-glucosidase inhibitor).^[@ref29]^

###### IC~50~ and *K*~i~ (in μM) Values for Synthesized Compounds and Standards Miglitol and DNJ

  compound            α-glucosidase (rice)   β-glucosidase (rice)   α-galactosidase (bovine)   β-galactosidase (bovine)   α-mannosidase (Jack bean)
  ---------- -------- ---------------------- ---------------------- -------------------------- -------------------------- ---------------------------
  miglitol   IC~50~   0.100                  342                    NI                         NI                         NI
  *K*~i~     0.081    320                    NI                     NI                         NI                         
  DNJ        IC~50~   0.05                   327                    890                        NI                         NI
  *K*~i~     0.012    450                    1030                   NI                         NI                         
  **1**      IC~50~   0.069                  336                    695                        NI                         NI
  *K*~i~     0.012    628                    896                    NI                         NI                         
  **2**      IC~50~   0.159                  428                    993                        NI                         NI
  *K*~i~     0.129    456                    932                    NI                         NI                         
  **3a**     IC~50~   0.075                  285                    632                        NI                         NI
  *K*~i~     0.098    240                    1300                   NI                         NI                         
  **3b**     IC~50~   0.032                  84                     84                         81                         79
  *K*~i~     0.025    14                     14                     23                         80                         
  **3c**     IC~50~   0.033                  89                     73                         81                         66
  *K*~i~     0.028    59                     58                     33                         90                         
  **3d**     IC~50~   0.035                  251                    84                         113                        73
  *K*~i~     0.028    152                    68                     134                        43                         
  **3e**     IC~50~   0.037                  286                    86                         73                         91
  *K*~i~     0.022    191                    75                     68                         56                         
  **3f**     IC~50~   0.038                  291                    12                         64                         98
  *K*~i~     0.031    93                     04                     38                         61                         
  **3g**     IC~50~   0.049                  286                    88                         86                         101
  *K*~i~     0.042    135                    71                     38                         95                         
  **4a**     IC~50~   0.036                  120                    578                        NI                         NI
  *K*~i~     0.033    798                    1650                   NI                         NI                         
  **4b**     IC~50~   0.030                  295                    93                         191                        63
  *K*~i~     0.024    214                    82                     69                         33                         
  **4c**     IC~50~   0.032                  298                    86                         58                         74
  *K*~i~     0.025    171                    58                     39                         65                         
  **4d**     IC~50~   0.032                  287                    87                         96                         78
  *K*~i~     0.027    215                    55                     84                         58                         
  **4e**     IC~50~   0.032                  241                    82                         89                         91
  *K*~i~     0.026    ND                     61                     79                         61                         
  **4f**     IC~50~   0.037                  \>1000                 88                         74                         86
  *K*~i~     0.024    ND                     67                     52                         58                         
  **4g**     IC~50~   0.034                  \>1000                 87                         76                         68
  *K*~i~     0.019    ND                     54                     54                         69                         

From [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, it is evident that the α-glucosidase inhibitory activity of N-alkylated iminosugars **3b**--**g** and **4b**--**g** was significantly improved as compared to their parent compounds **3a** and **4a**, respectively. At the same time, N-alkylated compounds **3b**--**g**/**4b**--**g** were found to inhibit other enzymes in a micromolar range ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}) and suggest fall in selectivity of enzyme inhibition for them in contrast to **3a** and **4a**, respectively. Elongation of alkyl chain from ethyl to dodecyl, however, showed decrease in α-glucosidase inhibition with each higher homologue of alkyl chain.

### Antifungal Activity {#sec2.3.2}

The use of 1,2,3-triazole moiety in advanced antifungal drug designing provided a platform to synthesize new antifungal agents containing 1,2,3-triazole pharmacophore.^[@ref30]^ In view of this, we have investigated the spiro-iminosugars **1**, **2**, **3a**--**g**, and **4a**--**g** for their antifungal activities against *C. albicans* in comparison to a well-known marketed antifungal drug, namely, amphotericine b, recommended for infection of *C. albicans* ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). The MIC value of **3a** (0.85 μg/mL) is found to be less than that of amphotericine b (1.25 μg/mL), whereas the value of **4a** (0.025 μg/mL) was found to be ∼50 times higher active than that of amphotericine b. Compounds **1** (2.5 μg/mL) and **2** (1.25 μg/mL) are, respectively, either weak or comparatively active with the marketed drug.

###### Antifungal Activities of **1**, **2**, **3a**--**g**, and **4a**--**g**[a](#t2fn1){ref-type="table-fn"}

  compound         MIC      compound   MIC      compound   MIC
  ---------------- -------- ---------- -------- ---------- --------
  amphotericin b   1.25     **1**      2.5      **2**      1.25
  **3a**           0.85     **3b**     \>1.25   **3c**     \>2.5
  **3d**           \>2.5    **3e**     \>2.5    **3f**     \>1.25
  **3g**           1.25     **4a**     0.025    **4b**     \>1.25
  **4c**           0.025    **4d**     0.020    **4e**     \>1.25
  **4f**           \>1.25   **4g**     \>1.25               

Minimum inhibition concentration (MIC) values in μg/mL.

Among N-alkylated derivatives, compound **4c** (MIC = 0.025 μg/mL) was found to be comparably active to parent molecule **4a**, whereas compound **4d** (MIC = 0.020 μg/mL) showed higher activity than **4a**. The MIC values of compounds **3b**--**g** ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}) are higher than those of amphotericine b (1.25 μg/mL), whereas for **4b**--**g**, various MIC values are found. Compounds **4b** and **4e**--**g** (MIC \> 1.25 μg/mL) are weakly or less active than **4a**. Thus, all other N-alkyl derivatives (except **4b** and **4c**) were found to be less antifungal than their parent compounds. The confocal images of all screened compounds showed aggregation of the molecules at the fungal cell surface and exhibited cell wall disruption ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}).

![Confocal images of compounds **1**, **2**, **3a**--**g**, and **4a**--**g** with yeast cell. The red arrows show site of cell wall disruption.](ao-2017-01299m_0005){#fig5}

Molecular Docking Studies {#sec2.4}
-------------------------

### Glycosidases and Ligand Interactions {#sec2.4.1}

The observed biological activities were supported by molecular docking studies. Thus, molecular interaction of inhibitor molecules with rice α-glucosidase was analyzed by docking studies. Binding scores of synthesized spiro-iminosugars (**1**, **2**, **3a**--**g**, and **4a**--**g**) are illustrated in [Table S3](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01299/suppl_file/ao7b01299_si_001.pdf) and binding poses on the active site of α-glucosidase (rice) enzyme are shown in [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}. Corroboration of binding free energies with the inhibition kinetic studies indicated that among synthesized compounds, molecules **1**, **2**, **3a**, and **4a** are potent competitive inhibitors of rice α-glucosidase. All screened molecules with their respective conformations (^1^*C*~4~ or ^4^*C*~1~ for piperidine iminosugars) form favorable contacts with binding pocket of α-glucosidase. Analysis of polar contacts and other weak interactions (electrostatic and π-interaction) of these compounds showed that the higher binding affinity is presumably attributed to the formation of higher number of stable intermolecular hydrogen bonds between the reactive group of compounds and ASP204, ILE205, SER469, ARG473, ASN477, and LYS478 at the binding site of the enzyme ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}). However, several π-alkyl interactions observed between ligand aromatic ring and interacting residues of enzyme assist polar interaction. In case of N-alkyl derivatives **3b**--**g** and **4b**--**g**, it has been observed that binding of these ligands with enzyme was unfavorable as compared to the parental compounds ([Table S3](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01299/suppl_file/ao7b01299_si_001.pdf)). This suggests that addition of N-alkyl chain to **3a** and **4a** reduces the number of interactions with binding site residues. As a result, changes in functional group lead to differential interactions with binding pocket of enzyme. Minute deviation in biological activity with respect to molecular docking observations might be due to variations in ligand conformation, in vitro assay condition, solvation of ligand, and ligand charge state.

![Docking images and binding energies (B.E.) of iminosugars with α-glucosidase (rice).](ao-2017-01299m_0006){#fig6}

### Molecular Docking Studies for Antifungal Activity {#sec2.4.2}

Antifungal potential of spiro-iminosugars (**1**, **2**, **3a**, **4a**, **4c**, and **4d**) was analyzed using a docking simulation in relation with amphotericine b as a positive control. The positive binding energy (10.5 kcal/mol) for amphotericine b suggests that its interaction with ergosterol is predominated by unfavorable interaction over favorable contacts ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}). Analogously, we have predicted binding of spiro-iminosugars with ergosterol, a component of fungal cell membranes, which might result in the disruption of the fungal cell wall and lead to fungal cell death. Compounds **1**, **2**, and **3a** showed approximately equal binding energies (−1.9, −1.8, and −1.8 kcal/mol) with ergosterol, whereas the highest binding energy of −2.2 kcal/mol was noticed for compound **4a**. All compounds exhibited π-alkyl interaction as shown in [Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}. The N-alkylated derivatives **4c** (B.E. −2.4 kcal/mol) and **4d** (B.E. −2.6 kcal/mol) ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}) exhibit strong binding with ergosterol as compared to their parent compound **4a**. This increase in binding energy in derivatives **4c** and **4d** than their parent iminosugar **4a** is in agreement with the in vitro antifungal data ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}).

![Docking of **1**, **2**, **3a**, **4a**, **4c**, and **4d** with ergosterol component of cell wall of *C. albicans* (binding energy (B.E.) is in kcal/mol).](ao-2017-01299m_0007){#fig7}

Conclusions {#sec3}
===========

In conclusion, the AAC reaction of 3-*O*-propargyl-3-azido-[d]{.smallcaps}-glucofuranose derivative (**IXd**) gave adduct **5** that was used as a common intermediate, by judicious manipulation of the 1,2- and 5,6-*O*-isopropylidene groups, in the synthesis of library of **s**piro-iminosugars (**1**, **2**, **3a**--**g**, and **4a**--**g**) linked with the 1,2,3-triazole-fused morpholine. The presence of two pharmacophores, such as iminosugar and triazole, showed dual biological activity. In addition, the synergetic effect of two pharmacophores led to augmentation of the glycosidase inhibitory as well as antifungal activity. Among 16 examples, the spiro-iminosugars **3a** and **4a** were found to be more potent inhibitors of α-glucosidase than miglitol as well as showed high antifungal activity against *C. albicans* than amphotericin b. The N-alkyl derivatives showed increase of α-glucosidase inhibition and enhancement of antifungal activity as compared to their respective parent iminosugar. Thus, the synthesized spiro-iminosugars may open a new era of potential chimeric drugs in comorbidity treatments.

Experimental Section {#sec4}
====================

General Methods for Synthesis {#sec4.1}
-----------------------------

Melting points were recorded using Thomas--Hoover melting point apparatus and are uncorrected. IR spectra were recorded with an FTIR spectroscope as a thin film or using KBr pellets and are expressed in cm^--1^. ^1^H NMR (300, 400, or 500 MHz) and ^13^C NMR (100 or 125 MHz) spectra were recorded using CDCl~3~, CD~3~OD, or D~2~O as solvent(s). Chemical shifts were reported in δ unit (parts per million) with reference to TMS as an internal standard, and coupling constant (*J*) values were given in Hertz. Optical rotations were measured using a polarimeter at 22 °C. High-resolution mass spectra (HRMS) were obtained in positive-ion electrospray ionization (ESI) mode using time-of-flight analyzer. Thin-layer chromatography was performed on precoated plates (0.25 mm, silica gel 60 F254). Column chromatography was carried out with silica gel (100--200 mesh). Reactions were carried out in oven-dried glassware under dry N~2~ atmosphere. Methanol, dichloromethane, and THF were purified and dried according to reported methods. Petroleum ether (PE) was a distillation fraction between 40 and 60 °C. The 10% Pd/C was purchased from Aldrich. After neutralization, workup involves washing of combined organic layer with water and brine, drying over anhydrous sodium sulfate, and evaporating the solvent under reduced pressure, followed by vacuum drying.

### Synthesis of **6** {#sec4.1.1}

Compound **5** (2.5 g, 7.07 mmol) was dissolved in 60% aq AcOH (15 mL) and heated at 60 °C for 3 h. RM was directly concentrated in a rotary evaporator under vacuum, and the thick residue obtained was dissolved in ethyl acetate (EtOAc) and washed with saturated aq NaHCO~3~ and distilled water. The organic layer was evaporated to dryness to give a thick syrup. Column purification of the syrup was done with eluting of a 7:3 mixture of ethyl acetate and petroleum ether to ease the synthesis of **6** (2.04 g, 92%) as a solid. *R*~*f*~ = 0.15, EtOAc; mp = 66--68 °C; \[α\]~D~^22^ = −21.7 (*c* 0.108, methanol); IR (KBr, ν, cm^--1^) 3433, 2987, 2937, 1639, 1554, 1458, 1379, 1091, 869, 732; ^1^H NMR (300 MHz, CDCl~3~) δ 7.56 (s, 1H), 6.26 (d, *J* = 3.6 Hz, 1H), 4.98 (AB~q~, *J* = 15.1 Hz, 2H), 4.65 (d, *J* = 3.6 Hz, 1H), 4.39 (AB~q~, *J* = 12.6 Hz, 2H), 4.28 (d, *J* = 8.8 Hz, 1H), 3.74 (dd, *J* = 11.6, 3.2 Hz, 1H), 3.64 (dd, *J* = 11.6, 5.1 Hz, 1H), 3.12 (ddd, *J* = 8.8, 5.1, 3.2 Hz, 1H), 1.60 (s, 3H), 1.35 (s, 3H); ^13^C NMR (125 MHz, CDCl~3~) δ 131.6, 128.3, 113.5, 105.7, 85.2, 81.1, 69.9, 68.9, 65.9, 64.1, 62.7, 26.9, 26.5; HRMS calculated for C~13~H~19~N~3~O~6~Na \[M + Na\]^+^ 336.1169, Found: 336.1167.

### Synthesis of **7** {#sec4.1.2}

Compound **6** (0.800 g, 2.55 mmol) was dissolved in dry DCM (10 mL), to which Bu~2~SnO (0.063 g, 10% mol) was added and stirred for 10 min, followed by pinchwise addition of TsCl (0.535 g, 2.81 mmol) and dropwise addition of TEA (1.07 mL, 7.66 mmol). Reactions were maintained at RT for 1 h and then quenched by 1 M aq HCl solution and extracted by dichloromethane (2 × 10 mL). The dichloromethane layer was concentrated, and the obtained thick residue was purified by column chromatography using EtOAc/PE (3:2) as mobile phase **7** (1.16 g, 97%) observed as a white solid. *R*~*f*~ = 0.56, EtOAc/PE (4:1); mp = 86--88 °C; \[α\]~D~^22^ = −23.2 (*c* 0.102, methanol); IR (KBr, ν, cm^--1^) 3433, 2985, 2933, 1597, 1494, 1452, 1357, 1176, 1095, 985, 819, 667, 553; ^1^H NMR (500 MHz, CDCl~3~) δ 7.75 (d, *J* = 8.1 Hz, 2H), 7.53 (s, 1H), 7.33 (d, *J* = 8.1 Hz, 2H), 6.16 (d, *J* = 3.5 Hz, 1H), 4.94 (s, 2H), 4.56 (d, *J* = 3.5 Hz, 1H), 4.38 (AB~q~, *J* = 12.6 Hz, 2H), 4.22 (d, *J* = 8.9 Hz, 1H), 4.15 (dd, *J* = 10.4, 2.4 Hz, 1H), 4.06 (dd, *J* = 10.4, 5.8 Hz, 1H), 3.42 (ddd, *J* = 10.4. 5.8, 2.4 Hz, 1H), 2.44 (s, 3H), 1.57 (s, 3H), 1.34 (s, 3H). ^13^C NMR (125 MHz, CDCl~3~) δ 145.0, 132.4, 131.5, 129.9 (2C), 128.4, 128.0 (2C), 113.7, 105.8, 85.2, 80.4, 71.8, 69.7, 67.0, 65.9, 62.7, 27.1, 26.5, 21.7; HRMS calculated for C~20~H~25~N~3~O~8~SNa \[M + Na\]^+^ 490.1255, Found: 490.1254.

### Synthesis of **8** {#sec4.1.3}

Under N~2~ atmosphere, into a mixture of **7** (1.0 g, 2.14 mmol), NaN~3~ (0.166 g, 2.57 mmol), and TABI (0.079 g, 10% mol), dry DMF (10 mL) was added and heated to 95 °C for 3 h. RM was concentrated directly, water (5 mL) was added, and extraction was carried out by EtOAc (2 × 10 mL). A thick residue was obtained, which was further purified by EtOAc/PE (3:2) as mobile phase for column chromatography. A white solid **8** was observed (0.644 g, 89%). *R*~*f*~ = 0.65, EtOAc/PE (4:1); mp = 151--153 °C; \[α\]~D~^22^ = −32.0 (*c* 0.104, methanol); IR (KBr, ν, cm^--1^) 3400, 2989, 2935, 2104, 1664, 1440, 1381, 1220, 1093, 929, 869, 771, 553; ^1^H NMR (500 MHz, CDCl~3~) δ 7.53 (s, 1H), 6.23 (d, *J* = 3.5 Hz, 1H), 5.03 (d, *J* = 15.2 Hz, 1H), 4.93 (d, *J* = 15.2 Hz, 1H), 4.65 (d, *J* = 3.5 Hz, 1H), 4.43 (d, *J* = 12.7 Hz, 1H), 4.33 (d, *J* = 12.7 Hz, 1H), 4.29 (d, *J* = 8.5 Hz, 1H), 3.46 (dd, *J* = 10.5, 3.2 Hz, 1H), 3.42 (dd, *J* = 10.5, 5.2 Hz, 1H) 3.17 (ddd, *J* = 8.5, 5.2, 3.2 Hz, 1H), 1.60 (s, 3H), 1.35 (s, 3H). ^13^C NMR (125 MHz, CDCl~3~) δ 131.0, 128.4, 113.8, 105.6, 85.4, 82.1, 69.6, 68.0, 66.4, 62.8, 54.0, 27.0, 26.5; HRMS calculated for C~13~H~18~N~6~O~5~Na \[M + Na\]^+^ 361.1231, Found: 361.1237.

### Synthesis of **1** {#sec4.1.4}

To compound **8** (200 mg, 0.591 mmol), 75% aq TFA (5 mL, precooled to 0 °C) was added and stirred for 3 h. After concentration under vacuum, saturated aq NaHCO~3~ (5 mL) was added and extracted with EtOAc (2 × 5 mL). The organic layer was filtered through a 60--120 mesh silica bed with eluting EtOAc. A thick residue was observed on concentration, which was directly dissolved in distilled methanol (5 mL) and hydrogenated using 10% Pd/C (catalytic) at RT and 80 psi pressure of H~2~ for 24 h and filtered through a celite bed. MeOH was concentrated and purified by column chromatography to obtain a syrup with MeOH/CHCl~3~ (1:4) as mobile phase. Amorphous solid (0.107 g, 71% over two steps) of **1** was observed. *R*~*f*~ = 0.50, MeOH/CHCl~3~ (1:4); mp = 235 °C (dec.); \[α\]~D~^22^ = −42.8 (*c* 0.101, methanol); IR (KBr, ν, cm^--1^); 2968, 2106, 1639, 1450, 1377, 1217, 1166, 1095, 916, 868, 748, 700; ^1^H NMR (500 MHz, D~2~O) δ 7.60 (s, 1H), 4.93 (AB~q~, *J* = 15.8 Hz, 2H), 4.52 (ddd, *J* = 8.1, 3.4, 1.7 Hz, 1H), 4.47 (dd, *J* = 8.1, 2.4 Hz, 1H), 4.47 (d, *J* = 8.1, 2.5 Hz, 1H), 4.43 (d, *J* = 1.7 Hz, 1H), 4.39 (d, *J* = 12.8 Hz, 1H), 4.32 (d, *J* = 12.8 Hz, 1H), 3.70 (dd, *J* = 14.2, 2.5 Hz, 1H), 3.52--3.38 (m, 3H); ^13^C NMR (125 MHz, D~2~O) δ 133.2, 128.8, 75.1, 68.6, 67.1, 66.3, 65.9, 62.0, 46.5, 45.7; HRMS calculated for C~10~H~17~N~4~O~4~ \[M + H\]^+^ 257.1249, Found: 257.1255.

### Synthesis of **9** {#sec4.1.5}

Compound **8** (0.300 g, 0.886 mmol) in THF (5 mL) was added dropwise to a precooled (0 °C) suspension of NaH (0.042 g, 1.06 mmol) in THF (5 mL), followed by drowise addition of BnBr (0.120 mL, 0.975 mmol). The reaction was maintained initially at 0 °C for 30 min and then at RT for 2.5 h. The reaction was quenched with saturated aq ammonium chloride, extracted with EtOAc (2 × 5 mL), and concentrated in vacuo at reduced pressure, which gave a thick residue. Purification of this residue was done by column chromatography using EtOAc/PE (2:3) as mobile phase. A white solid **9** (0.284 g, 75%) was observed. *R*~*f*~ = 0.40 EtOAc/PE (2:3); mp = 108--110 °C; \[α\]~D~^22^ = −80.6 (*c* 0.105, methanol); IR (KBr, ν, cm^--1^); 2968, 2935, 2106, 1550, 1450, 1494, 1095, 1018, 868, 748; ^1^H NMR (500 MHz, CDCl~3~) δ 7.55 (s, 1H), 7.35--7.29 (m, 3H), 7.07 (dd, *J* = 6.3, 2.9 Hz, 2H), 6.21 (d, *J* = 3.4 Hz, 1H), 4.83 (d, *J* = 14.8 Hz, 1H), 4.57 (d, *J* = 12.1 Hz, 1H), 4.45 (d, *J* = 10.8 Hz, 1H), 4.42 (d, *J* = 3.4 Hz, 1H), 4.38 (d, *J* = 8.9 Hz, 1H), 4.12 (d, *J* = 14.8 Hz, 1H), 4.05 (d, *J* = 12.1 Hz, 1H), 3.85 (dt, *J* = 8.9, 2.8 Hz, 1H), 3.73 (dd, *J* = 13.5, 2.8 Hz, 1H), 3.58 (d, *J* = 10.8 Hz, 1H), 3.50 (dd, *J* = 13.5, 2.8 Hz, 1H), 1.62 (s, 3H), 1.37 (s, 3H); ^13^C NMR (125 MHz, CDCl~3~) δ 136.6, 132.0, 128.6(2C), 128.5, 128.2, 128.0(2C), 113.8, 105.9, 85.4, 77.8, 71.9, 70.0, 65.6, 62.4, 50.4, 27.4, 26.8; HRMS calculated for C~20~H~24~N~6~O~5~Na \[M + Na\]^+^ 451.1705, Found: 451.1711.

### Synthesis of **2** {#sec4.1.6}

Compound **9** (0.200 g, 0.591 mmol) was dissolved in 75% aq TFA (5 mL, precooled to 0 °C), stirred for 3 h, and concentrated under vacuum. EtOAc (5 mL) was added and organic layer was washed with saturated aq NaHCO~3~. The EtOAc layer was filtered through a 60--120 mesh silica bed with eluting more EtOAc and concentrated. The thick residue obtained was directly dissolved in acetone/water (8:2, 15 mL) and cooled to 0 °C. NaIO~4~ (0.573 g, 2.68 mmol) was pinchwise added to this mixture over 30 min, and the reaction was maintained at 0 °C for 1 h and then at RT for another 1 h. The reaction was quenched by cooling to 0 °C and adding ethylene glycol and then concentrated on a rotary evaporator. Water was added and extracted twice by EtOAc (6 × 5 mL each). A concentrated and thick residue obtained was directly dissolved in MeOH (5 mL) and hydrogenated using 10% Pd/C (catalytic) and stirred at 120 psi pressure for 30 h. RM was filtered through celite, concentrated, and purified by MeOH/CHCl~3~ (1:4) as mobile phase. Compound **2** was obtained as a white solid (0.071 g, 68% over two steps). *R*~*f*~ = 0.54, MeOH/CHCl~3~ (1:4); mp = 185--187 °C; \[α\]~D~^22^ = −78.5 (*c* 0.101, methanol); IR (KBr, ν, cm^--1^); 3308, 2928, 1674, 1450, 1246, 1093, 833, 758; ^1^H NMR (500 MHz, D~2~O, 72 °C) δ 7.67 (s, 1H), 5.08 (d, *J* = 15.0 Hz, 1H), 4.90 (d, *J* = 15.0 Hz, 1H), 4.72 (d, *J* = 3.2 Hz, 1H), 4.53 (d, *J* = 13.0 Hz, 1H), 4.20 (bs, 1H), 4.19 (d, *J* = 13.0 Hz, 1H), 3.32 (d, *J* = 13.8 Hz, 1H), 3.10 (dd, *J* = 14.4, 1.5 Hz, 1H) 2.97 (dd, *J* = 14.4, 2.0 Hz, 1H), 2.93 (d, *J* = 13.8 Hz, 1H); ^13^C NMR (125 MHz, D~2~O) δ 133.5, 128.7, 71.3, 68.1, 64.8, 63.4, 61.8, 50.0, 48.5; DEPT-135, down (48.5, 50.0, 61.8, 64.8), up (68.2, 71.3, 128.8); HRMS calculated for C~9~H~15~N~4~O~3~ \[M + H\]^+^ 227.1144, Found: 227.1142.

### Synthesis of **10** {#sec4.1.7}

Acetone/water (8:2, 15 mL) was added to **6** (0.700 g, 2.23 mmol) and cooled to 0 °C. NaIO~4~ (0.573 g, 2.68 mmol) was added pinchwise to this mixture over 30 min and stirred at 0 °C for 1 h and then at RT for another 1 h. RM was cooled to 0 °C and ethylene glycol was added to quench the reaction and then RM was concentrated on a rotary evaporator. Water (5 mL) was added and extracted by ethyl acetate (2 × 10 mL). Concentrated organic layer gave a syrup that was dissolved in MeOH (10 mL), cooled to 0 °C, and NaBH~4~ (0.101 g, 2.68 mmol) was added portionwise over a period of 20 min. The reaction was maintained at 0 °C for another 30 min and then quenched by saturated aq NH~4~Cl and extracted by EtOAc (2 × 10 mL). The EtOAc layer was concentrated and purified by column chromatography EtOAc/PE (1:1) as mobile phase. A white solid **10** was observed (0.556 mg, 88% over two steps). *R*~*f*~ = 0.26 in ethyl EtOAc; mp = 122--124 °C \[α\]~D~^22^ = +44.3 (*c* 0.101 methanol); IR (KBr, ν, cm^--1^); 3232, 3130, 2949, 1545, 1448, 1379, 1242, 1168, 1101, 991, 871, 759; ^1^H NMR (500 MHz, CDCl~3~) δ 7.58 (s, 1H), 6.36 (d, *J* = 3.6 Hz, 1H), 5.09 (d, *J* = 15.2 Hz, 1H), 4.87 (d, *J* = 15.2 Hz, 1H), 4.84 (d, *J* = 3.6 Hz, 1H), 4.53 (t, *J* = 5.4 Hz, 1H), 4.38 (d, *J* = 12.7 Hz, 1H), 4.14 (d, *J* = 12.7 Hz, 1H), 3.38--3.30 (m, 2H), 1.62 (s, 4H), 1.38 (s, 3H); ^13^C NMR (125 MHz, CDCl~3~) δ 130.6, 128.3, 113.5, 105.7, 85.3, 83.4, 68.4, 66.9, 62.7, 60.3, 26.8, 26.4; HRMS calculated for C~12~H~17~N~3~O~5~Na \[M + Na\]^+^ 306.1068, Found: 306.1074.

### Synthesis of **11** {#sec4.1.8}

Compound **10** (20.500 g, 1.77 mmol) was dissolved in dry dichloromethane (10 mL) and cooled to 0 °C, to which dry pyridine (0.426 mL, 5.30 mmol) was added dropwise followed by addition of TsCl (0.403 g, 2.12 mmol) pinchwise over 15 min. The reaction was maintained at 0 °C for 30 min and then at RT for 3 h. The reaction was quenched by 1 M aq HCl solution and extracted using dichloromethane (2 × 10 mL). The organic layer was concentrated, and the thick residue obtained was purified by column chromatography as mobile phase. A white solid **11** was observed (0.733 g, 95%). *R*~*f*~ = 0.50 in EtOAc/PE (2:3); mp = 165--167 °C; \[α\]~D~^22^ = +14.12 (*c* 0.103 methanol); IR (KBr, ν, cm^--1^); 3373, 2991, 2924, 1595, 1492, 1440, 1373, 1178, 1097, 981, 868, 763, 665, 555; ^1^H NMR (500 MHz, CDCl~3~) δ 7.66 (d, *J* = 8.3 Hz, 2H), 7.53 (s, 1H), 7.31 (d, *J* = 8.3 Hz, 2H), 6.25 (d, *J* = 3.5 Hz, 1H), 4.96 (d, *J* = 15.1 Hz, 1H), 4.87 (d, *J* = 15.1 Hz, 1H), 4.66 (d, *J* = 3.5 Hz, 1H), 4.56 (t, *J* = 5.5 Hz, 1H), 4.24 (AB~q~, *J* = 12.7 Hz, 1H), 4.00 (dd, *J* = 10.8, 5.5 Hz, 1H), 3.69 (dd, *J* = 10.8, 5.5 Hz, 1H), 2.44 (s, 3H), 1.56 (s, 3H), 1.34 (s, 3H); ^13^C NMR (125 MHz, CDCl~3~) δ 145.3, 132.2, 131.2, 130.0 (2C), 128.5, 128.0 (2C), 113.8, 106.1, 85.0, 79.9, 68.7, 67.0, 66.2, 62.6, 27.0, 26.5, 21.7; HRMS calculated for C~19~H~24~N~3~O~7~S \[M + H\]^+^ 438.1335, Found: 438.1338.

### Synthesis of **12** {#sec4.1.9}

To a mixture of **11** (0.600 g, 1.37 mmol), NaN~3~ (0.107 g, 1.65 mmol), and TBAI (0.051 g, 10% mol) dry DMF (10 mL) was added under N~2~ environment and heated at 95 °C for 6 h. The mixture was concentrated directly on a rotary evaporator, added with water (5 mL), extracted by EtOAc (2 × 10 mL), concentrated, and purified by EtOAc/PE (1:1) as mobile phase using column chromatography. A white solid **12** was observed (0.363 g, 86%). *R*~*f*~ = 0.55, EtOAc/PE (1:1); mp = 191--193 °C; IR \[α\]~D~^22^ = +70.5 (*c* 0.104 methanol); IR (KBr, ν, cm^--1^); 2991, 2941, 2094, 1654, 1546, 1448, 1379, 1230, 1166, 1107, 991, 854, 763, 665, 549; ^1^H NMR (500 MHz, CDCl~3~) δ 7.58 (s, 1H), 6.37 (d, *J* = 3.6 Hz, 1H), 5.03 (d, *J* = 15.2 Hz, 1H), 4.84 (d, *J* = 15.2 Hz, 1H), 4.78 (d, *J* = 3.6 Hz, 1H), 4.53 (dd, *J* = 7.7, 3.8 Hz, 1H), 4.31 (d, *J* = 12.8 Hz, 1H), 4.15 (d, *J* = 12.8 Hz, 1H), 3.25 (dd, *J* = 13.0, 3.8 Hz, 1H), 2.84 (dd, *J* = 13.0, 7.7 Hz, 1H), 1.61 (s, 3H), 1.37 (s, 3H); ^13^C NMR (125 MHz, CDCl~3~) δ 130.9, 128.5, 113.7, 106.1, 85.2, 82.3, 68.6, 66.9, 62.7, 50.3, 27.1, 26.5; HRMS calculated for C~12~H~16~N~6~O~4~Na \[M + Na\]^+^ 331.1130, Found: 331.1138.

### Synthesis of **3a** {#sec4.1.10}

Compound **12** (0.300 g, 0.591 mmol) was dissolved in 75% aq TFA/H~2~O (5 mL, precooled to 0 °C), stirred at RT for 3 h, concentrated on a rotary evaporator under vaccum followed by EtOAc addition, and the organic layer was washed with 10% aq NaHCO~3~ solution. Finally, the organic layer was filtered through a 60--120 mesh silica bed with eluting EtOAc and concentrated to obtain a thick residue. The thick residue was directly dissolved in methanol (5 mL), hydrogenated using 10% Pd/C (catalytic), and stirred at 100 psi pressure for 30 h. The reaction mass was filtered through celite, concentrated, and purified by MeOH/CHCl~3~ (1:4) as mobile phase. A white solid **3a** (0.189 g, 86% over two steps) was observed. *R*~*f*~ = 0.45 MeOH/CHCl~3~ (1:4); mp = 229--231 °C (dec.); IR (KBr, ν, cm^--1^) 3311, 3117, 2960, 2893, 1688, 1599, 1450, 1247, 1111, 1066, 999, 858, 761, 596; ^1^H NMR (500 MHz, D~2~O) δ 7.71 (s, 1H), 4.93 (s, 2H), 4.48 (dd, *J* = 10.8, 4.8 Hz, 1H), 4.43 (s, 2H), 3.29 (dd, *J* = 13.4, 4.8 Hz, 2H), 2.84 (dd, *J* = 13.4, 10.8 Hz, 2H); ^13^C NMR (125 MHz, D~2~O) δ 135.1, 128.9, 70.9(2C), 65.6, 61.9, 61.5, 46.0(2C); HRMS calculated for C~9~H~15~N~4~O~3~ \[M + H\]^+^ 227.1139, Found: 227.1145.

### Synthesis of **13** {#sec4.1.11}

Dry dichloromethane (10 mL) and **6** (0.500 g, 1.60 mmol) were mixed together and cooled to 0 °C, to which imidazole (0.239 g, 3.51 mmol) and TBDMSCl (0.264 g, 1.76 mmol) were added and the reaction was maintained at RT for 2 h. The reaction was quenched by 1 M aq HCl solution and extracted by dichloromethane (4 × 10 mL); organic layers were mixed and concentrated, followed by purification of the obtained thick syrup by column chromatography using EtOAc/PE (1:4) as mobile phase to obtain a colorless thick syrup **13** (0.648 g, 95%). *R*~*f*~ = 0.60, EtOAc; \[α\]~D~^22^ = −21.2 (*c* 0.101, methanol); IR (KBr, ν, cm^--1^); 3462, 2929, 1464, 1379, 1249, 1165, 1095, 1006, 837, 777, 669; ^1^H NMR (500 MHz, CDCl~3~) δ 7.56 (s, 1H), 6.22 (d, *J* = 3.5 Hz, 1H), 5.00 (d, *J* = 14.7 Hz, 16H), 4.85 (d, *J* = 14.7 Hz, 1H), 4.54 (d, *J* = 12.3 Hz, 1H), 4.51 (d, *J* = 3.5 Hz, 1H), 4.34 (d, *J* = 12.3 Hz, 1H), 4.14 (d, *J* = 9.0 Hz, 1H), 3.77 (dd, *J* = 10.2, 3.1 Hz, 1H), 3.72 (dd, *J* = 10.2, 5.1 Hz, 1H), 3.51--3.44 (m, 1H, after D~2~O ex., it appears as ddd *J* = 9.0, 5.1, 3.1 Hz), 2.68 (d, *J* = 4.8 Hz, 1H, ex. with D~2~O), 1.58 (s, 3H), 1.35 (s, 3H), 0.88 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H); ^13^C NMR (125 MHz, CDCl~3~) δ 131.9, 128.4, 113.4, 105.9, 85.3, 79.7, 70.1, 68.9, 65.4, 64.3, 62.7, 27.1, 26.6, 25.9 (3C), 18.3, −5.40, −5.45; HRMS calculated for C~19~H~33~N~3~O~6~SiNa \[M + Na\]^+^ 450.2021, Found: 450.2022.

### Synthesis of **14** {#sec4.1.12}

Compound **13** (0.600 g, 1.40 mmol) was dissolved in dry dichloromethane (10 mL) and cooled to 0 °C, to which dry pyridine (0.283 mL, 3.51 mmol) was added slowly, followed by addition of triflic anhydride (0.259 mL, 1.54 mmol, diluted in 2 mL DCM) dropwise over 10 min and catalytic DMAP. The reaction was maintained at 0 °C for 1 h, quenched by 1 M aq HCl solution, and extracted twice with 5 mL of dichloromethane each time and concentrated. A thick syrup (0.810 g) was obtained, to which, without purification, NaN~3~ (0.129 g, 2.00 mmol, considering 95% yield of OTf intermediate) and dry DMF (5 mL) were added. The reaction mass was heated to 65 °C for 1 h, concentrated directly on a rotary evaporator, water (5 mL) was added, extracted with ethyl acetate (2 × 5 mL), and evaporated. The obtained thick syrup was purified by column chromatography using EtOAc/PE (1:4) as mobile phase, and an off-white solid **14** (0.584 g, 92% over two steps) was obtained. *R*~*f*~ = 0.37 in EtOAc/PE (1:1); mp = 119--121 °C; \[α\]~D~^22^ = +50.5 (*c* 0.103 methanol); IR (KBr, ν, cm^--1^); 2987, 2933, 2858, 2112, 1643, 1464, 1379, 1249, 1170, 1095, 1037, 837, 775; ^1^H NMR (500 MHz, CDCl~3~) δ 7.60 (s, 1H), 6.43 (d, *J* = 3.6 Hz, 1H), 5.14 (d, *J* = 15.2 Hz, 1H), 4.88 (d, *J* = 15.2 Hz, 1H), 4.85 (d, *J* = 3.6 Hz, 1H), 4.57 (d, *J* = 2.0 Hz, 1H), 4.35 (d, *J* = 12.7 Hz, 1H), 4.11 (d, *J* = 12.7 Hz, 1H), 3.83 (dd, *J* = 10.1, 6.7 Hz, 1H), 3.77 (dd, *J* = 10.1, 6.7 Hz, 1H), 3.55 (td, *J* = 6.7, 2.0 Hz, 2H), 1.60 (s, 3H), 1.38 (s, 3H), 0.91 (s, 12H), 0.09 (s, 3H), 0.08 (s, 3H); ^13^C NMR (125 MHz, CDCl~3~) δ 130.3, 128.4, 113.3, 105.6, 85.0, 80.5, 67.7, 67.1, 63.2, 62.5, 60.6, 26.8, 26.3, 25.8 (3C), 18.1, −5.51, −5.55; HRMS calculated for C~19~H~33~N~6~O~5~Si \[M + H\]^+^ 453.2276, Found: 453.2286.

### Synthesis of **4a** {#sec4.1.13}

TFA (75% aq, 5 mL, precooled to 0 °C) was added to compound **14** (0.500 mg, 1.10 mmol), stirred at 0 °C for 3 h, and concentrated under vacuum and saturated aq NaHCO~3~ (5 mL), followed by EtOAC (5 mL) addition. The reaction was extracted twice with EtOAc (2 × 5 mL) and the separated organic layer was filtered through a 60--120 mesh silica bed with eluting ethyl acetate and concentrated. A thick residue was obtained, which was directly dissolved in distilled MeOH (10 mL), hydrogenated using 10% Pd/C (cat.), stirred at 120 psi pressure for 24 h, filtered through celite, concentrated, and purified by MeOH/CHCl~3~ (2:3) as mobile phase. Compound **4a** was obtained as a white solid (0.220 g, 78% over two steps). *R*~*f*~ = 0.35, MeOH/CHCl~3~ (2:3); mp = 114--116 °C; \[α\]~D~^22^ = −27.5 (*c* 0.102, methanol); IR (KBr, ν, cm^--1^); 3308, 2928, 1674, 1450, 1093, 939, 758; ^1^H NMR (500 MHz, D~2~O) δ 7.65 (s, 1H), 5.02 (AB~q~, *J* = 15.5 Hz, 2H), 4.32 (AB~q~, *J* = 12.5 Hz, 2H), 4.11 (d, *J* = 2.6 Hz, 1H), 4.05 (t, *J* = 3.3 Hz, 1H), 3.71 (dd, *J* = 11.0, 6.5 Hz, 1H), 3.68 (dd, *J* = 11.0, 6.5 Hz, 1H), 3.65--3.62 (m, 1H), 3.60 (dd, *J* = 14.4, 3.3 Hz, 1H), 3.07 (dd, *J* = 14.4, 3.3 Hz, 1H); ^13^C NMR (125 MHz, D~2~O) δ 133.0, 128.4, 68.2, 68.1, 66.6, 63.3, 62.1, 60.4, 56.0, 46.5; HRMS calculated for C~10~H~17~N~4~O~4~ \[M + H\]^+^ 257.1249, Found: 257.1255.

General Method for N-Alkylation {#sec4.2}
-------------------------------

Iminosugar **3a**/**4a** (1.0 equiv) was dissolved in dry DMF (0.5 mL), followed by addition of K~2~CO~3~ (2.2 equiv) and alkyl halide (1.1 equiv). The reaction mass was heated under N~2~ atmosphere and concentrated on a rotary evaporator under high vaccum, followed by column purification using CHCl~3~ and MeOH system as a mobile phase on silica gel 100--200 mesh size.

### Synthesis of **3b** {#sec4.2.1}

The reaction of **3a** (0.020 g, 88.40 μmol), K~2~CO~3~ (0.027 g, 194.49 μmol), and bromoethane (0.007 mL, 97.25 μmol) in DMF was maintained at 80 °C for 1 h. Usual workup and purification by column chromatography using CHCl~3~/MeOH (1:9) as mobile phase gave **3b** (0.021 g, 95%) as a white solid. *R*~*f*~ = 0.52, CHCl~3~/MeOH (1:4); mp = 147--149 °C; ^1^H NMR (400 MHz, CD~3~OD) δ 7.47 (s, 1H), 4.72 (s, 2H), 4.44 (dd, *J* = 11.2, 4.9 Hz, 2H), 4.25 (s, 2H), 2.91 (dd, *J* = 11.2, 4.9 Hz, 2H), 2.47 (q, *J* = 7.2 Hz, 2H), 2.09 (t, *J* = 11.2 Hz, 2H), 1.04 (t, *J* = 7.2 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD) δ 135.0, 127.4, 71.0 (2C), 65.9, 61.3, 61.2, 55.1 (2C), 51.1, 10.7; HRMS (ESI) *m*/*z* calculated for C~11~H~19~N~4~O~3~ (M + H)^+^ 255.1452, Found: 255.1451.

### Synthesis of **3c** {#sec4.2.2}

The reaction of **3a** (0.020 g, 88.40 μmol), K~2~CO~3~ (0.027 g, 194.49 μmol), and *n*-bromobutane (0.010 mL, 97.25 μmol) in DMF was carried out at 80 °C for 1 h. Usual workup and purification by column chromatography using CHCl~3~/MeOH (1:9) as mobile phase gave **3c** (0.024 g, 98%) as a white solid. *R*~*f*~ = 0.55, CHCl~3~/MeOH (1:4); mp = 156--158 °C; ^1^H NMR (400 MHz, CD~3~OD) δ 7.47 (s, 1H), 4.72 (s, 2H), 4.43 (dd, *J* = 11.2, 4.9 Hz, 2H), 4.25 (s, 2H), 2.90 (dd, *J* = 11.2, 4.9 Hz, 2H), 2.39 (q, *J* = 7.2 Hz, 2H), 2.09 (t, *J* = 11.2 Hz, 2H), 1.49--1.37 (m, 2H), 1.28 (sextate, *J* = 7.2 Hz, 2H), 0.87 (t, *J* = 7.2 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD) δ 135.0, 127.3, 71.0 (2C), 65.9, 61.3, 61.2, 57.1, 55.6 (2C), 28.6, 20.2, 12.9; HRMS (ESI) *m*/*z* calculated for C~13~H~23~N~4~O~3~ (M + H)^+^: 283.1765, Found: 283.1769.

### Synthesis of **3d** {#sec4.2.3}

The reaction of **3a** (0.020 g, 88.40 μmol), K~2~CO~3~ (0.027 g, 194.49 μmol), and *n*-bromohexane (0.014 mL, 97.25 μmol) in DMF was carried out at 80 °C for 1 h. Usual workup and purification by column chromatography using CHCl~3~/MeOH (1:9) as mobile phase gave **3d** (0.024 g, 89%) as a white solid. *R*~*f*~ = 0.56, CHCl~3~/MeOH (1:4); mp = 153--155 °C; ^1^H NMR (400 MHz, CD~3~OD) δ 7.47 (s, 1H), 4.72 (s, 2H), 4.43 (dd, *J* = 11.2, 4.9 Hz, 2H), 4.25 (s, 2H), 2.90 (dd, *J* = 11.2, 4.9 Hz, 2H), 2.38 (q, *J* = 7.2 Hz, 2H), 2.09 (t, *J* = 11.2 Hz, 2H), 1.49--1.37 (m, 2H), 1.30--1.21 (m, 6H), 0.82 (t, *J* = 7.2 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD) δ 135.0, 127.5, 70.9 (2C), 65.9, 61.3, 61.2, 57.4, 55.5 (2C), 31.5, 26.8, 26.3, 22.3, 13.0; HRMS (ESI) *m*/*z* calculated for C~15~H~27~N~4~O~3~ (M + H)^+^: 311.2084, Found: 311.2078.

### Synthesis of **3e** {#sec4.2.4}

The reaction of **3a** (0.020 g, 88.40 μmol), K~2~CO~3~ (0.027 g, 194.49 μmol), and *n*-bromooctane (0.017 mL, 97.25 μmol) in DMF was carried out at 80 °C for 1 h. Usual workup and purification by column chromatography using CHCl~3~/MeOH (1:9) as mobile phase gave **3e** (0.028 g, 94%) as a white solid. *R*~*f*~ = 0.58, CHCl~3~/MeOH (1:4); mp = 141--143 °C; ^1^H NMR (400 MHz, CD~3~OD) δ 7.48 (s, 1H), 4.73 (s, 2H), 4.44 (dd, *J* = 11.5, 4.9 Hz, 2H), 4.26 (s, 2H), 2.91 (dd, *J* = 11.5, 4.9 Hz, 2H), 2.42--2.36 (m, 2H), 2.10 (t, *J* = 11.5 Hz, 2H), 1.49--1.41 (m, 2H), 1.30--1.18 (m, 10H), 0.82 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, D~2~O) δ 135.0, 127.4, 71.0 (2C), 65.9, 61.3, 61.2, 57.4, 55.6 (2C), 31.6, 29.2, 29.0, 27.1, 26.4, 22.3, 13.0; HRMS (ESI) *m*/*z* calculated for C~17~H~31~N~4~O~3~ (M + H)^+^: 339.2391, Found: 339.2390.

### Synthesis of **3f** {#sec4.2.5}

The reaction of **3a** (0.020 g, 88.40 μmol), K~2~CO~3~ (0.027 g, 194.49 μmol), and *n*-bromodecane (0.020 mL, 97.25 μmol) in DMF was carried out at 60 °C for 1 h. Usual workup and purification by column chromatography using CHCl~3~/MeOH (1:9) as mobile phase gave **3f** (0.029 g, 92%) as a white solid. *R*~*f*~ = 0.60, CHCl~3~/MeOH (1:4); mp = 147--149 °C; ^1^H NMR (400 MHz, CD~3~OD) δ 7.47 (s, 1H), 4.72 (s, 2H), 4.43 (dd, *J* = 11.5, 4.4 Hz, 2H), 4.25 (s, 2H), 2.90 (dd, *J* = 11.5, 4.4 Hz, 2H), 2.39 (App. triplet, *J* = 7.7 Hz, 2H), 2.09 (t, *J* = 11.5 Hz, 2H), 1.50--1.40 (m, 2H), 1.31--1.12 (m, 14H), 0.81 (t, *J* = 7.7 Hz, 3H); ^13^C NMR (125 MHz, D~2~O) δ 135.0, 127.4, 71.0 (2C), 66.0, 61.3, 61.2, 57.4, 55.6 (2C), 31.7, 29.33, 29.30, 29.2, 29.1, 27.1, 26.4, 22.3, 13.0; HRMS (ESI) *m*/*z* calculated for C~19~H~35~N~4~O~3~ (M + H)^+^: 367.2704, Found: 367.2703.

### Synthesis of **3g** {#sec4.2.6}

The reaction of **3a** (0.020 g, 88.40 μmol), K~2~CO~3~ (0.027 g, 194.49 μmol), and *n*-bromododecane (0.023 mL, 97.25 μmol) in DMF was carried out at 60 °C for 1 h. Usual workup and purification by column chromatography using CHCl~3~/MeOH (1:9) as mobile phase gave **3g** (0.031 g, 90%) as a white solid. *R*~*f*~ = 0.66, CHCl~3~/MeOH (1:4); mp = 214--216 °C; ^1^H NMR (400 MHz, CD~3~OD) δ 7.47 (s, 1H), 4.72 (s, 2H), 4.43 (dd, *J* = 11.2, 4.8 Hz, 2H), 4.25 (s, 2H), 2.90 (dd, *J* = 11.2, 4.8 Hz, 2H), 2.38 (App. t, *J* = 7.7 Hz, 2H), 2.09 (t, *J* = 11.2 Hz, 2H), 1.50--1.40 (m, 2H), 1.30--1.13 (m, 18H), 0.80 (t, *J* = 7.7 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD) δ 135.0, 127.3, 71.0 (2C), 66.0, 61.3, 61.2, 57.4, 55.6 (2C), 31.7, 29.4, 29.32, 29.30, 29.2, 29.1, 27.1, 26.4, 22.3, 13.0; HRMS (ESI) *m*/*z* calculated for C~21~H~39~N~4~O~3~ (M + H)^+^: 395.3017, Found: 395.3017.

### Synthesis of **4b** {#sec4.2.7}

The reaction of **4a** (0.020 g, 78.05 μmol), K~2~CO~3~ (0.024 g, 171.70 μmol), and bromoethane (0.006 mL, 85.85 μmol) in DMF was carried out at 60 °C for 2 h. Usual workup and purification by column chromatography using CHCl~3~/MeOH (2:3) as mobile phase gave **4b** (0.020 g, 93%) as a thick syrup. *R*~*f*~ = 0.46, CHCl~3~/MeOH (2:3); \[α\]~D~^22^ = +0.5 (*c* 0.15, methanol); ^1^H NMR (400 MHz, CD~3~OD) δ 7.45 (s, 1H), 4.85 (d, *J* = 15.0 Hz, 1H), 4.74 (d, *J* = 15.0 Hz, 1H), 4.24 (d, *J* = 4.7 Hz, 1H), 4.16 (AB~q~, *J* = 12.2 Hz, 1H), 4.10 (dd, *J* = 8.0, 3.6 Hz, 1H), 3.71 (dd, *J* = 11.0, 6.0 Hz, 1H), 3.67 (dd, *J* = 11.0, 4.7 Hz, 1H), 3.30 (App. q, *J* = 4.7 Hz, 1H), 3.21 (dd, *J* = 12.8, 3.6 Hz, 1H), 2.85--2.71 (m, 3H), 1.06 (t, *J* = 7.1 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD) δ 133.6, 127.3, 78.1, 70.5, 69.8, 65.5, 64.9, 62.0, 61.7, 58.3, 51.6, 10.2; HRMS (ESI) *m*/*z* calculated for C~12~H~21~N~4~O~4~ (M + H)^+^: 285.1557, Found: 285.1557.

### Synthesis of **4c** {#sec4.2.8}

The reaction of **4a** (0.020 g, 78.05 μmol), K~2~CO~3~ (0.024 g, 171.70 μmol), *n*-bromobutane (0.010 mL, 85.85 μmol) in DMF at 60 °C for 2 h. Usual workup and purification by column chromatography using CHCl~3~/MeOH (2:3) as mobile phase gave **4c** (0.021 g, 89%) as a thick syrup. *R*~*f*~ = 0.50, CHCl~3~/MeOH (2:3); \[α\]~D~^22^ = +6.4 (*c* 0.13, methanol); ^1^H NMR (400 MHz, CD~3~OD) δ 7.45 (s, 1H), 4.84 (d, *J* = 15.0 Hz, 1H), 4.72 (d, *J* = 15.0 Hz, 1H), 4.28 (d, *J* = 4.3 Hz, 1H), 4.18 (d, *J* = 12.2 Hz, 1H), 4.13 (dd, *J* = 8.1, 3.9 Hz, 1H), 4.11 (d, *J* = 12.2 Hz, 1H), 3.70 (dd, *J* = 12.0, 4.3 Hz, 1H), 3.68 (dd, *J* = 12.0, 4.3 Hz, 1H), 3.25 (dd, *J* = 12.9, 3.9 Hz, 1H), 3.13 (dd, *J* = 6.9, 3.9 Hz, 1H) 2.76 (dd, *J* = 12.9, 7.3 Hz, 1H) (s, 3H), 2.74--2.61 (m, 2H), 1.55--1.41 (m, 2H), 1.28 (sextate, *J* = 7.4 Hz), 0.87 (t, *J* = 7.3 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~) δ 136.1, 129.5, 72.9, 72.2, 67.5, 67.4, 65.0, 63.9, 60.4, 55.6, 54.0, 30.6, 22.4, 15.2; HRMS (ESI) *m*/*z* calculated for C~14~H~25~N~4~O~4~ (M + H)^+^: 313.1870, Found: 313.1870.

### Synthesis of **4d** {#sec4.2.9}

The reaction of **4a** (0.020 g, 78.05 μmol), K~2~CO~3~ (0.024 g, 171.70 μmol), and *n*-bromohexane (0.012 mL, 85.85 μmol) in DMF was carried out at 60 °C for 2 h. Usual workup and purification by column chromatography using CHCl~3~/MeOH (2:3) as mobile phase gave **4d** (0.024 g, 90%) as a thick syrup. *R*~*f*~ = 0.52, CHCl~3~/MeOH (2:3); \[α\]~D~^22^ = +1.7 (*c* 0.15, methanol); ^1^H NMR (400 MHz, CD~3~OD) δ 7.45 (s, 1H), 4.84 (d, *J* = 15.0 Hz, 1H), 4.72 (d, *J* = 15.0 Hz, 1H), 4.28 (d, *J* = 4.3 Hz, 1H), 4.18 (d, *J* = 12.1 Hz, 1H), 4.12 (dd, *J* = 7.9, 3.7 Hz, 1H), 4.11 (d, *J* = 12.1 Hz, 1H), 3.69 (dd, *J* = 11.2, 4.3 Hz, 1H), 3.67 (dd, *J* = 11.2, 4.3 Hz, 1H), 3.25 (App. q, *J* = 4.3 Hz, 1H), 3.13 (dd, *J* = 12.9, 3.7 Hz, 1H), 2.80--2.60 (m, 3H), 1.55--1.42 (m, 2H), 1.32--1.20 (m, 6H), 0.82 (t, *J* = 6.7 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD) δ 136.0, 129.5, 72.9, 72.2, 67.5, 67.4, 64.9, 63.9, 60.4, 55.9, 54.0, 33.8, 29.0, 28.3, 24.6, 15.3; HRMS (ESI) *m*/*z* calculated for C~16~H~29~N~4~O~4~ (M + H)^+^: 341.2183, Found: 341.2193.

### Synthesis of **4e** {#sec4.2.10}

The reaction of **4a** (0.020 g, 78.05 μmol), K~2~CO~3~ (0.024 g, 171.70 μmol), and *n*-bromooctane (0.015 mL, 85.85 μmol) in DMF was carried out at 60 °C for 2 h. Usual workup and purification by column chromatography using CHCl~3~/MeOH (2:3) as mobile phase gave **4e** (0.026 g, 92%) as a thick syrup. *R*~*f*~ = 0.53, CHCl~3~/MeOH (2:3); \[α\]~D~^22^ = +7.5 (*c* 0.14, methanol); ^1^H NMR (400 MHz, CD~3~OD) δ 7.45 (s, 1H), 4.84 (d, *J* = 15.0 Hz, 1H), 4.73 (d, *J* = 15.0 Hz, 1H), 4.28 (d, *J* = 4.9 Hz, 1H), 4.16 (d, *J* = 12.1 Hz, 1H), 4.13 (dd, *J* = 8.1, 3.9 Hz, 1H), 4.11 (d, *J* = 12.1 Hz, 1H), 3.68 (dd, *J* = 11.3, 6.2 Hz, 1H), 3.66 (dd, *J* = 11.3, 4.9 Hz, 1H), 3.25 (App. q, *J* = 4.9 Hz, 1H), 3.13 (dd, *J* = 12.9, 3.9 Hz, 1H), 2.80--2.60 (m, 3H), 1.58--1.43 (m, 2H), 1.32--1.15 (m, 10H), 0.81 (t, *J* = 6.8 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD) δ 136.0, 129.5, 72.9, 72.2, 67.5, 67.4, 64.9, 63.9, 60.4, 55.9, 54.0, 33.9, 31.5, 31.6, 31.3, 29.3, 28.3, 24.6, 15.3; HRMS (ESI) *m*/*z* calculated for C~18~H~33~N~4~O~4~ (M + H)^+^: 369.2496, Found: 369.2502.

### Synthesis of **4f** {#sec4.2.11}

The reaction of **4a** (0.020 g, 78.05 μmol), K~2~CO~3~ (0.024 g, 171.70 μmol), and *n*-bromodecane (0.018 mL, 85.85 μmol) in DMF was carried out at 60 °C for 2 h. Usual workup and purification by column chromatography using CHCl~3~/MeOH (2:3) as mobile phase gave **4f** (0.28 g, 90%) as a thick syrup. *R*~*f*~ = 0.55, CHCl~3~/MeOH (2:3); \[α\]~D~^22^ = +6.6 (*c* 0.16, methanol); ^1^H NMR (400 MHz, CD~3~OD) δ 7.45 (s, 1H), 4.84 (d, *J* = 15.0 Hz, 1H), 4.73 (d, *J* = 15.0 Hz, 1H), 4.28 (d, *J* = 4.9 Hz, 1H), 4.18 (d, *J* = 12.1 Hz, 1H), 4.13 (dd, *J* = 8.5, 3.9 Hz, 1H), 4.11 (d, *J* = 12.1 Hz, 1H), 3.70 (dd, *J* = 11.2, 6.2 Hz, 1H), 3.66 (dd, *J* = 11.2, 4.9 Hz, 1H), 3.25 (App. q, *J* = 4.9 Hz, 1H), 3.13 (dd, *J* = 12.9, 3.9 Hz, 1H), 2.74--2.61 (m, 2H), 2.76 (dd, *J* = 12.9, 8.5 Hz, 1H), 1.55--1.42 (m, 2H), 1.30--1.12 (m, 14H), 0.80 (t, *J* = 6.8 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD) δ 136.0, 129.5, 72.9, 72.2, 67.5, 67.4, 64.9, 63.9, 60.4, 55.9, 54.0, 33.9, 31.7, 31.6, 31.55, 31.3, 29.3, 24.6, 15.3; HRMS (ESI) *m*/*z* calculated for C~20~H~37~N~4~O~4~ (M + H)^+^: 397.2809, Found: 397.2820.

### Synthesis of **4g** {#sec4.2.12}

The reaction of **4a** (0.020 g, 78.05 μmol), K~2~CO~3~ (0.024 g, 171.70 μmol), and *n*-bromododecane (0.021 mL, 85.85 μmol) in DMF was carried out at 60 °C for 2 h. Usual workup and purification by column chromatography using CHCl~3~/MeOH (2:3) as mobile phase gave **4g** (0.029 g, 89%) as a thick syrup. *R*~*f*~ = 0.59, CHCl~3~/MeOH (2:3); \[α\]~D~^22^ = +18.8 (*c* 0.10, methanol); ^1^H NMR (400 MHz, CD~3~OD) δ 7.45 (s, 1H), 4.84 (d, *J* = 15.0 Hz, 1H), 4.73 (d, *J* = 15.0 Hz, 1H), 4.29 (d, *J* = 4.3 Hz, 1H), 4.18 (d, *J* = 12.1 Hz, 1H), 4.13 (dd, *J* = 8.0, 3.9 Hz, 1H), 4.11 (d, *J* = 12.1 Hz, 1H), 3.70 (dd, *J* = 11.2, 5.2 Hz, 1H), 3.66 (dd, *J* = 11.2, 4.9 Hz, 1H), 3.25 (App. q, *J* = 4.9 Hz, 1H), 3.13 (dd, *J* = 12.9, 3.9 Hz, 1H), 2.76 (dd, *J* = 12.9, 8.0 Hz, 1H), 2.74--2.60 (m, 2H), 1.55--1.45 (m, 2H), 1.30--1.13 (m, 18H), 0.80 (t, *J* = 6.8 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD) δ 133.8, 127.3, 70.6, 70.0, 65.3, 65.1, 62.7, 61.6, 58.2, 53.6, 51.8, 31.7, 29.4, 29.35, 29.3, 29.1, 27.1, 26.0, 22.3, 13.0; HRMS (ESI) *m*/*z* calculated for C~22~H~41~N~4~O~4~ (M + H)^+^: 425.3122, Found: 425.3135.

Conformational Analysis Protocol for DFT Method {#sec4.3}
-----------------------------------------------

To investigate conformational preferences of compounds **3a**, **3c**, **4a**, and **4c** and to corroborate our NMR experimental observations, we have performed quantum chemical calculations using the density functional theory (DFT) method. The initial geometries (^2^*C*~5~ and ^5^*C*~2~ conformations) for compounds **3a** and **3c** and (^1^*C*~4~ and ^4^*C*~1~ conformations) for compounds **4a** and **4c** have been generated using molecular modeling Spartan'14 software (wavefunction.in). Automated complete geometry optimizations were performed using the DFT method by employing B3LYP/6-31 G\*\* basic set function on Spartan'14 software. Pictorial presentations of DFT-optimized geometries of compounds have been made using Mercury 3.7 software.

Methodology Used for Biological Activities {#sec4.4}
------------------------------------------

### Glycosidase Inhibitory Activity {#sec4.4.1}

Glycosidase inhibition assay for compounds **1**, **2**, **3a**--**g**, and **4a**--**g** was carried out by mixing 0.1 U cm^--3^ each of α-,β-glucosidase, α-,β-galactosidase, and α-mannosidase, and the samples were incubated for 1 h at 37 °C. Enzyme action for α/β-galactosidase was initiated by addition of 10 mM *p*-nitrophenyl-α-/β-[d]{.smallcaps}-galactopyranoside (*p*NPG) as a substrate in 200 mM sodium acetate buffer. The reaction was incubated at 37 °C for 10 min and stopped by adding 2 cm^3^ of 200 mM borate buffer of pH 9.8. α-Mannosidase activity was initiated by addition of 10 mM *p*-nitrophenyl-α-[d]{.smallcaps}-mannopyranoside as a substrate in 100 mM citrate buffer of pH 4.5. The reaction was incubated at 37 °C for 10 min and stopped by adding 2 cm^3^ of 200 mM borate buffer of pH 9.8. Initiation of α-glucosidase activity was done by addition of 10 mM *p*-nitrophenyl-α-[d]{.smallcaps}-glucopyranoside in 100 mM phosphate buffer of pH 6.8 and stopped by adding 2 cm^3^ of 0.1 M Na~2~CO~3~ after an incubation of 10 min at 37 °C. Glycosidase activity was determined by measuring absorbance of the *p*-nitrophenol released from *p*NPG at 420 nm using Molecular Devices Spectramax M5 mulitmode plate reader. One unit of glycosidase activity is defined as the amount of enzyme that hydrolyzed 1 mM of *p*-nitrophenyl pyranoside per minute under assay condition.

Inhibition constant (*K*~i~) values were determined by spectrophotometrically measuring the residual hydrolytic activities of the glycosidases in the presence of compounds. Each assay was performed in the appropriate buffer at the optimal pH for the enzymes. The reactions were initiated by addition of enzyme to a solution of the substrate in the absence or presence of various concentrations of inhibitor. Approximate values of *K*~i~ were determined using a fixed concentration of substrate (around the *K*~M~ value for the different glycosidases) and various concentrations of inhibitor. Full *K*~i~ determinations and enzyme inhibition mode were determined from the slope of Lineweaver--Burk plots and double reciprocal analysis.

Antifungal Activity {#sec4.5}
-------------------

### Minimal Inhibition Concentration (MIC) Assay {#sec4.5.1}

Fungal strains *Candida albicans* NCIM 3557 were procured from National Chemical Lab, Repository. Using the multipipette dispense, 100 μL of LB medium was dispensed in all wells of microliter plate. The plate and lid were labeled, and 100 μL of 2× antibiotic solutions was pipette into wells in column 1. Using the multipipette set at 100 μL, the antibiotics were mixed into the wells of column 1 by sucking up and down six to seven times. A volume of 100 μL from column 1 was withdrawn and added to column 2. This made column 2 a twofold dilution of column 1, column 3 a twofold dilution of column 3, and so on. Similar procedure was repeated for the test compounds **1**, **2**, **3a**--**g**, and **4a**--**g**. The plates were incubated at 30 °C for 24 h and scanned with an ELISA plate reader. All experiments were run in triplicate, and standard deviations were determined.

Bright-Field Images {#sec4.6}
-------------------

### *Candida albicans* {#sec4.6.1}

SC5314 strain obtained from MTCC (National Chemical Lab, Pune) was inoculated in six-well sterile plates. The glass slides were made grease-free thoroughly. Each compound (5 μL) in its subinhibitory concentration was added to each well along with control. Compounds **1**, **2**, **3a**--**g**, and **4a**--**g** were added and incubated at 37 °C for 24 h. The cells were treated and fixed using 2% paraformaldehyde. The glass slides were washed with 1× PBS buffer and imaged using confocal microscopy.

Methodology Used for Docking Studies {#sec4.7}
------------------------------------

Three dimensional (3D) models of rice α/β glucosidase, rice α/β galactosidase, and Jack bean α-mannosidase were built by comparative modeling using MODELER 9 v4.^[@ref31]^ Crystallographic structures of homologous protein were considered as a template to predict the structures of enzymes, which were further assessed by the Ramachandran plot analysis. Structures of enzymes and synthesized molecules were energy-minimized using GROMOS43B1 energy field. Receptor and ligand molecules were prepared for docking simulation by adding hydrogens and assigning Kollman charges. Likewise, the ligands were established by assigning the Gasteiger charges and nonpolar hydrogens. Structures of receptor and ligand are converted from pdb to pdbqt format using AutoDock 4.2.^[@ref32]^ Grid was set around the active site of enzymes with a dimension of 20 × 20 × 20 Å^3^ using Autogrid module of Autodock program. Binding score was calculated by the Lamarckian genetic algorithm (LGA), which uses a set of 30 structurally known protein--ligand complexes with experimentally determined binding constants to calibrate empirical free-energy functions. Parameters were set to the LGA calculation of 10 000 runs, whereas energy evaluations were set to 1 500 000 and 27 000 generations (repetition of process). The obtained docked poses and intermolecular interactions were gathered and analyzed using PyMol visualize (PyMol Molecular Graphics System, version 1.2r3 pre, Schrodinger LLC).

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.7b01299](http://pubs.acs.org/doi/abs/10.1021/acsomega.7b01299).^1^H and ^13^C spectra of new compounds, DFT-optimized coordinates and hydrogen-bonding parameters, binding energy of **1**, **2**, **3a**--**g**, and **4a**--**g** with glycosidases, Lineweaver--Burk plots ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01299/suppl_file/ao7b01299_si_001.pdf))CIF files for **2** and **3a** ([CIF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01299/suppl_file/ao7b01299_si_002.cif)) ([CIF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01299/suppl_file/ao7b01299_si_003.cif))
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A number of examples wherein piperidine, pyrrolidine, and azetidine spirocycled with various groups are known to be biologically important molecules.

The best example of such multifunctional drug is artemisnin--quinine conjugate hybrid drug, which is more effective against drug-sensitive and drug-resistant malaria than the individual drugs.

Only **3c** and **4c** were optimized, as all N-alkyl derivatives **3b--g** and **4b--g** are showing nearly equivalent *J* values as in **3c** and **4c**, respectively.
